Bronchogen Dosage Guide: Protocols, Calculator & Safety

Dose Range

10 mg oral capsule, 1-2 daily for 10-30 days

Stacking Notes

Bronchogen sits within the Khavinson bioregulator family and is most commonly stacked with other tetrapeptides in rotating cycles. Below we describe both the community-standard approach and the evidence-graded alternative.

Khavinson multi-bioregulator rotation (community standard)

Within the Russian longevity and bioregulator community, Bronchogen is typically cycled alongside Pinealon, Epitalon, Thymogen, Vilon, and Livagen in 10-day cycles separated by 60–90 day washouts. The theoretical argument is that different tetrapeptides target different tissues and their effects combine additively. There is no controlled-trial evidence of synergy; the pattern rests on theoretical framework.

A typical respiratory-focused Khavinson rotation might run:

• Days 1–10: Bronchogen 20 mg oral/sublingual daily
• Days 11–70: Washout
• Days 71–80: Thymogen 100 mcg SC or intranasal daily (for immune support)
• Days 81–140: Washout
• Days 141–150: Epitalon 5–10 mg SC daily (general anti-aging)
• Days 151–210: Washout
• Repeat Bronchogen cycle at 6-month interval

Cycling rather than continuous use matches the Khavinson convention.

Evidence-graded respiratory stack (preferred)

If your goal is actual respiratory health, the stack looks nothing like a Khavinson rotation. In descending order of evidence:

1. Smoking cessation — highest-evidence intervention for any smoker. Nothing else matters nearly as much.
2. Pulmonary rehabilitation — structured exercise and breathing training with RCT support in COPD.
3. Inhaled short-acting bronchodilators (albuterol/salbutamol) — immediate relief of bronchospasm.
4. Inhaled long-acting bronchodilators (LABA like formoterol; LAMA like tiotropium) — maintenance therapy.
5. Inhaled corticosteroids where indicated.
6. Vaccination (influenza, pneumococcal, COVID-19, RSV for older adults).
7. Environmental exposure reduction (air quality, occupational exposures, wood smoke, indoor air).
8. N-acetylcysteine (NAC) 600–1200 mg daily — modest evidence for chronic bronchitis symptom reduction.

Bronchogen does not displace any tier. It is a speculative add-on for users who have completed the evidence-graded interventions.

Stacking with NAC and mucolytics

Community users sometimes combine Bronchogen with NAC, carbocysteine, or erdosteine for additive mucolytic effect. The theoretical rationale is complementary mechanisms — NAC alters mucus disulphide chemistry, Bronchogen (claimed) regenerates epithelial cilia. There is no evidence of harm from the combination. There is also no controlled evidence of synergy beyond the individual effects.

Stacking with inhaled therapy

No pharmacokinetic interactions are expected between Bronchogen and inhaled β2-agonists, muscarinic antagonists, or corticosteroids — the inhaled drugs act locally and systemic exposure is minimal. Adding Bronchogen to an existing inhaler regimen is safe from an interaction standpoint but should not substitute for the inhaled therapy.

Stacking with oral respiratory medications

Theophylline, leukotriene receptor antagonists (montelukast, zafirlukast), PDE4 inhibitors (roflumilast), and macrolide antibiotics (azithromycin) used for COPD maintenance have no documented interactions with Bronchogen. The peptide's rapid hydrolysis to amino acids makes pharmacokinetic interactions theoretically unlikely.

Contraindicated combinations

Do not use Bronchogen as a substitute for smoking cessation therapy. Do not use it to delay bronchodilator initiation in newly diagnosed obstructive disease. Do not use in place of antibiotics during acute bacterial exacerbations. Do not use as a substitute for biologic therapy in severe asthma.

Stacking with other Khavinson bioregulators

Running Bronchogen sequentially with Thymogen (immune support) and Epitalon (general anti-aging) is the most common community pattern. There is no evidence of harm at Khavinson-convention doses; there is also no evidence of specific benefit beyond the framework-level theoretical additivity. If budget is limited, prioritise the bioregulator with the strongest evidence base for your specific goal — Epitalon for general aging markers, Thymogen for registered-pharmaceutical immune modulation, Bronchogen for the narrower respiratory-support niche.

Dosage Notes

Bronchogen dosing derives from Khavinson-group Russian publications and post-Soviet commercial product labelling, not from modern pharmacokinetic studies.

Oral/sublingual dosing (commercial capsule)

• 1 capsule (20 mg nominal) once daily
• Sublingual preferred — hold under tongue ~60 seconds for partial buccal absorption
• Empty stomach 30–45 min before first meal
• Duration: 10 days per cycle
• Washout: 60–90 days between cycles
• Seasonal pattern: Russian clinicians favour autumn entry (pre-winter) with occasional spring repeat

The 20 mg capsule contains undisclosed peptide content with excipient balance. Actual AEDP per capsule is typically 2–4 mg based on historical vendor disclosures.

Subcutaneous dosing (synthetic peptide)

For users with synthetic lyophilised AEDP peptide:

• Dose range: 2–5 mg SC once daily
• Injection site: Subcutaneous abdomen or thigh, rotating sites
• Duration: 10 consecutive days per cycle
• Washout: 60 days minimum

SC administration bypasses first-pass hydrolysis and delivers theoretically higher systemic exposure per milligram, though the PK data to quantify this difference does not exist in published literature.

Intranasal dosing

Not a conventional Khavinson route for Bronchogen. Some community users attempt intranasal based on Semax/Selank precedent, but there is no Khavinson-group protocol for Bronchogen intranasal delivery and no PK support.

Cycling rationale

The 10-days-on / 60-days-off pattern is uniform across the Khavinson tetrapeptide family. The theoretical argument is that short peptide pulses produce sustained transcriptional adjustments that outlast the dosing window, and continuous dosing might produce tolerance or off-target effects. Neither claim has been empirically tested; the pattern is conventional rather than optimised.

Seasonal considerations

The autumn-spring pattern described above is rooted in Russian clinical practice. The rationale is that respiratory infection burden peaks in winter, so immune and respiratory bioregulator cycles are positioned in the preceding months. Whether this timing matters biologically is unstudied — the seasonal framing may be as much about community ritual as evidence-based dosing.

Maximum dose

No established maximum. Russian literature uses 20 mg oral consistently. Do not exceed 20 mg oral or 5 mg SC daily without clinical reason.

Continuous dosing

Do not run continuous (365-day) cycles. Safety of continuous dosing has not been characterised.

Age considerations

Russian studies typically enrol older adults (60+) with chronic respiratory disease. Younger adults with normal respiratory function have less theoretical benefit. No paediatric use.

Renal and hepatic impairment

No formal dose adjustment published. The peptide is small and cleared through hydrolysis and renal excretion of amino acid metabolites. Avoid in significant renal impairment (eGFR <30) and decompensated hepatic disease pending modern PK data.